DK398283A - Fremgangsmaade til fremstilling af 1,4-dihydropyridinderivater eller farmaceutisk acceptable syreadditionssalte deraf - Google Patents

Fremgangsmaade til fremstilling af 1,4-dihydropyridinderivater eller farmaceutisk acceptable syreadditionssalte deraf Download PDF

Info

Publication number
DK398283A
DK398283A DK398283A DK398283A DK398283A DK 398283 A DK398283 A DK 398283A DK 398283 A DK398283 A DK 398283A DK 398283 A DK398283 A DK 398283A DK 398283 A DK398283 A DK 398283A
Authority
DK
Denmark
Prior art keywords
procedure
preparation
acid addition
addition salts
acceptable acid
Prior art date
Application number
DK398283A
Other languages
Danish (da)
English (en)
Other versions
DK398283D0 (da
Inventor
Simon Fraser Campbell
Peter Edward Cross
John Kendrick Stubbs
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DK398283D0 publication Critical patent/DK398283D0/da
Publication of DK398283A publication Critical patent/DK398283A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK398283A 1982-09-04 1983-09-01 Fremgangsmaade til fremstilling af 1,4-dihydropyridinderivater eller farmaceutisk acceptable syreadditionssalte deraf DK398283A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8225245 1982-09-04

Publications (2)

Publication Number Publication Date
DK398283D0 DK398283D0 (da) 1983-09-01
DK398283A true DK398283A (da) 1984-03-05

Family

ID=10532689

Family Applications (1)

Application Number Title Priority Date Filing Date
DK398283A DK398283A (da) 1982-09-04 1983-09-01 Fremgangsmaade til fremstilling af 1,4-dihydropyridinderivater eller farmaceutisk acceptable syreadditionssalte deraf

Country Status (5)

Country Link
US (1) US4547502A (OSRAM)
EP (1) EP0107293A3 (OSRAM)
JP (1) JPS5976083A (OSRAM)
DK (1) DK398283A (OSRAM)
GR (1) GR78969B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL140573B1 (en) * 1982-12-21 1987-05-30 Pfizer Method of obtaining new dihydropyridine derivatives
US4568677A (en) * 1983-07-23 1986-02-04 Pfizer Inc. 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and antihypertensive agents
GB8415386D0 (en) * 1984-06-15 1984-07-18 Pfizer Ltd Therapeutic agents
IT1197012B (it) * 1986-07-29 1988-11-25 Boehringer Biochemia Srl 2-(aciltio) metil diidropiridine, un processo per la loro preparazione e composizioni farmaceutiche che le contengono
KR100728379B1 (ko) * 2005-09-30 2007-06-13 엘지전자 주식회사 엘씨디 패널의 편광판 부착방법 및 부착장치

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
BE756127A (fr) * 1969-09-12 1971-03-15 Hoechst Ag Ethers heterocycliques et leur preparation
US3943140A (en) * 1972-09-30 1976-03-09 Bayer Aktiengesellschaft 2,3,5,6-Tetracarboxy-1,4-dihydropyridine derivatives
US3946028A (en) * 1972-09-30 1976-03-23 Bayer Aktiengesellschaft 2,3,5,6-Tetracarboxy-4-pyridyl-1,4-dihydropyridine derivatives
DE2248150A1 (de) * 1972-09-30 1974-04-04 Bayer Ag Dihydropyridinpolyester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US3946027A (en) * 1972-09-30 1976-03-23 Bayer Aktiengesellschaft 3,5,6-Tricarboxy-4-pyridyl-1,4-dihydropyridine derivatives
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof
DE2658183A1 (de) * 1976-12-22 1978-07-06 Bayer Ag In 2-position substituierte 1,4- dihydropyridin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
US4307103A (en) * 1978-09-08 1981-12-22 Fujisawa Pharmaceutical Co., Ltd. Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
SE7910521L (sv) * 1979-12-20 1981-06-21 Haessle Ab Nya 2-metyl-6-substituerade-4-(2,3-disubstituerad fenyl)-1,4-dihydropyridin-3,5-diestrar med hypotesiva egenskaper, samt forfarande for deras framstellning, och farmaceutiska beredningar innehallande desamma
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine

Also Published As

Publication number Publication date
EP0107293A3 (en) 1984-06-06
DK398283D0 (da) 1983-09-01
GR78969B (OSRAM) 1984-10-02
US4547502A (en) 1985-10-15
JPS5976083A (ja) 1984-04-28
EP0107293A2 (en) 1984-05-02

Similar Documents

Publication Publication Date Title
DK149895C (da) Fremgangsmaade til fremstilling af alfa-aminoacylprolyl-ng-carboxy-argininaldehydderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK149308C (da) Analogifremgangs-maade til fremstilling af trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater eller farmaceutisk acceptablesyreadditionssalte deraf
DK74282A (da) Fremgangsmaade til fremstilling af imidazodiazepiner eller farmaceutisk acceptable syreadditionssalte deraf
DK337383D0 (da) Fremgangsmade til fremstilling af 4-amino-6,7-dimethoxyquinolin-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK106882A (da) Fremgangsmaade til fremstilling af 3,4-dihydro-5h-2,3-benzodiazepin-derivater eller farmaceutisk acceptable syreadditionssalte deraf
DK148795C (da) Anologifremgangsmaade til fremstilling af 3-(2-morpholino-ethyl-amino)-5-phenyl-pyridazin eller farmaceutisk acceptable syreadditionssalte deraf
DK493083A (da) Fremgangsmaade til fremstilling af 4-oxo-1,4-dihydronicotinsyrederivater eller salte deraf
DK163181C (da) Analogifremgangsmaade til fremstilling af n,n'-di(arylalkylen)alkylendiaminer eller farmaceutisk acceptable salte deraf
DK162842C (da) Analogifremgangsmaade til fremstilling af 1-perfluoralkyl-2-(1,2,4-triazol-1-yl)-ethanol-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK157451C (da) Analogifremgangsmaade til fremstilling af 2,4-diamino-6-alkoxybenzyl-5-methylpyridooe2,3-daapyrimidiner eller farmaceutisk acceptable syreadditionssalte deraf
DK321482A (da) Fremgangsmaade til fremstilling af 1-imidazolyl-2-phenyl-8-piperazinylphenoxy-octan-2-ol-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK134580A (da) Fremgangsmaade til fremstilling af 2,6-diaminonebulariner eller syreadditionssalte deraf
DK157135C (da) Analogifremgangsmaade til fremstilling af 1,2,4-triazol-forbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK15282A (da) Fremgangsmaade til fremstilling af (+)-enantiomere eller (+)(-)-racemiske 4a,9b-trans-hexahydro-1h-pyridoindol-derivater eller farmaceutisk acceptable syreadditionssalte deraf
DK150597C (da) Analogifremgangsmaade til fremstilling af 3,4-bis-substituerede 1,2,5-oxadiazol-2-oxider eller farmakologisk acceptable syreadditionssalte deraf
DK160875C (da) Analogifremgangsmaade til fremstilling af 3,7-diazabicyklooe3.3.1aa-nonanforbindelser eller farmaceutisk acceptable syreadditionssalte deraf
DK148281C (da) Analogifremgangsmaade til fremstilling af 8a-substituerede 8,8a-desoxy-8,8a-dihydrooleandomycin-forbindelser eller farmaceutiskacceptable syreadditionssalte deraf
DK438482A (da) Fremgangsmaade til fremstilling af indanderivater eller syreadditionssalte deraf
DK152754C (da) Analogifremgangsmaade til fremstilling af 1-acyl-8-(3-amino-2-hydroxypropoxy)-1,2,3,4-tetrahydroquinoliner eller farmaceutisk acceptable syreadditionssalte deraf
DK398283D0 (da) Fremgangsmade til fremstilling af 1,4-dihydropyridinderivater eller farmaceutisk acceptable syreadditionssalte deraf
DK586284D0 (da) Quinoloncarboxylsyre-derivater, fremgangsmaade til fremstilling deraf samt anvendelse af saadanne derivater som laegemiddel
DK157021C (da) Analogifremgangsmaade til fremstilling af 2,3-polymethylen-4-oxo-4h-pyrido- eller -azepinooe1,2-aaapyrimidiner eller farmaceutisk acceptable syreadditionssalte eller kvaternaere salte deraf
DK150481C (da) Analogifremgangsmaade til fremstilling af 3',4'-dihydro-spiro-(imidazolidin-4,1'-(2'h)-naphthalen)-5-on eller farmaceutisk acceptable syreadditionssalte deraf
DK151021C (da) Analogifremgangsmaade til fremstilling af 17,18-dehydro-apovincaminol-3',4',5'-trimethoxybenzoat eller farmaceutisk acceptable syreadditionssalte deraf
DK553982A (da) Fremgangsmaade til fremstilling af omt-esterderivater eller syreadditionssalte deraf

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment